SCHEMBL4824607

SCHEMBL4824607

CCOC(=O)CCNc1ccc(N)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
KDM4E B2RXH2 1/20 0.45
TOP2A P11388 1/20 0.45
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PTGER4 P35408 2/20 0.43
RAD52 P43351 1/20 0.42
PPIB P23284 1/20 0.41
PPIA P62937 1/20 0.41
PPID Q08752 1/20 0.41
PPIG Q13427 1/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAOA P21397 1/20 0.41
TNF P01375 4/20 0.40
BCL6 P41182 1/20 0.39
BCOR Q6W2J9 1/20 0.39
NLRP3 Q96P20 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826649 0.92 MAPT (0.55) MAPTKDM4ETOP2ACYP1A2CYP2C9
SCHEMBL4827101 0.88 MAPT (0.47) MAPTKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL9832178 0.85 SMN1; SMN2 (0.60) MAPTKDM4ETOP2ACYP1A2CYP2C9
SCHEMBL5930664 0.83 MAPT (0.42) MAPTKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL29264328 0.83 MAPT (0.47) MAPTKDM4ETOP2ACYP1A2CYP2C9
SCHEMBL4828295 0.82 MAPT (0.51) MAPTKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4826787 0.82 MAPT (0.51) MAPTKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4829925 0.80 MAPT (0.54) MAPTKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL8120801 0.79 MAPT (0.57) MAPTKDM4EPTGER4LMNACYP3A4
SCHEMBL4824465 0.79 TOP2A (0.49) MAPTKDM4ETOP2ACYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384432-B2 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions L'OREAL S.A. (FR) 2008-06-10 US claimed
US-20060021159-A1 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions L'OREAL S.A. (FR) 2006-02-02 US claimed
US-7384432-B2 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions L'OREAL S.A. (FR) 2008-06-10 US disclosed
US-7384432-B2 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions L'OREAL S.A. (FR) 2008-06-10 US disclosed
US-7384432-B2 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions L'OREAL S.A. (FR) 2008-06-10 US disclosed
US-20060021159-A1 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions L'OREAL S.A. (FR) 2006-02-02 US disclosed
EP-1580186-A1 Secondary p-phenylendiamines containing a carboxylic acid group, dye composition containing them, processes and uses L'OREAL (FR) 2005-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060021159-A1 Secondary para-phenylenediamines having a carboxyl group, dye compositions comprising the same, and dyeing processes using the compositions KRT18, CDC73, JUP MAPT 1947/4885KDM4E 599/4885TOP2A 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.